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Fig 1 Proptosis and exodeviation of the left eye  
Optic atrophy in the left eye  Fig 2 
Background Cyproterone is a derivative of progesterone with 
antiandrogenic, antigonadotropic, and progestagenic activity. High-dose 
preparations are indicated for use in the treatment of prostate cancer (200-
300 mg per day) and in the treatment of hypersexuality (50-600mg per day). 
Cyproterone blocks the binding of dihydrotestosterone (DHT) to prostatic 
cancer cells and exerts negative feedback on hypothalamic-pituitary axis by 
inhibiting luteinizing hormone (LH) secretion leading to decreased 
testosterone production. 
Lower-dose (2mg) cyproterone acetate (CPA) is available for use in women 
in combination with ethinylestradiol (0.035mg) for the treatment of severe 
acne and hirsutism.  
The suspicion that long term treatment with high daily doses of CPA could be 
responsible for the development of meningiomas was reported in 2008 by 
Froelich et al. He described multiple meningiomas in 9 female patients 
treated with CPA (50mg per day). Six patients were followed radiologically 
for a period exceeding 5 months (8 to 81) before treatment withdrawal. A 
significant increase in tumor size and/or the development of new lesions was 
observed in all cases.1 
A large, controlled, population-based study using data from The Health 
Improvement Network UK primary care database confirmed a significantly 
increased risk of meningioma in male patients taking high-dose CPA. 
However, these risk estimates were based on only four cases of 
meningioma. There was no significant association between meningioma and 
low-dose CPA use in female patients.2 
Nevertheless, the hypothesis that the exposure to high dose CPA increases 
the risk of meningioma is also supported by another large retrospective 
cohort study performed in a Spanish primary care database (BIFAP). Among 
2474 users of high dose CPA four meningioma cases were identified, 
resulting in an incidence rate which was significantly higher than that 
observed among the non-users and among users of low dose CPA. After 
adjusting for age and gender, patients exposed to high dose CPA showed an 
increased risk of meningioma of 11.4 (95% CI 4.3-30.8) as compared to non-
users.3 
One case report of Gonçalves et al reports a rapid regression of an 
incidental meningioma after discontinuation of a 10-year CPA treatment.4  
 
 
Case report We describe the clinical findings in a patient who has 
been treated with CPA 100mg per day for 23 years to reduce his 
aggressive sexual drive. The 42-year old male patient is known with 
mental retardation due to perinatal asphyxia. He was referred with 
slowly progressive unilateral proptosis and blindness. Best corrected 
visual acuity was 6/10 in the right eye and no light perception in the 
left eye. We noted an obvious proptosis and exodeviation of his left 
eye (Fig 1). Fundoscopy was unremarkable in the right eye and 
showed optic atrophy in the left eye (Fig 2).  
MRI of the brain revealed 11 meningiomas. One large meningioma 
located in the anterior temporal lobe extended into the orbit and 
caused proptosis and compression of the optic nerve leading to 
blindness of the left eye (Fig 3).  
The patient had been treated with a high dose of CPA (100mg per 
day) for more than 20 years.  
As written above there is a link between long term use of this drug 
and the development of meningiomas. The treatment with CPA was 
discontinued as literature suggests a regression of meningiomas after 
discontinuation of the drug. On a MRI follow-up 5 months after 
cessation of CPA, a regression of the largest meningiomas with a 
maximum of 10.7mm was noticed (Fig 4 and 5).  
Take Home Message 
- Always ask about general health and drug intake 
- Consider the potential risk of a meningioma in patients receiving CPA 
- Patients with existing meningioma or a history of meningioma should 
not be prescribed high-dose (>25mg/day) CPA). This warning does not 
apply to medicines that contain low-dose CPA 
- Withdrawal of CPA may induce regression of existing meningiomas.   
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Fig 3 Meningioma located in the anterior temporal lobe. It extends into the orbit and causes proptosis 
of the left eye and compression of the left optic nerve . 
Fig 4 Large lobulated meningioma in the right anterior fossa. The axial diameter was 60.8mm at 
presentation. Five months after discontinuation of CPA axial diameter was reduced to 50.08mm. 
Fig 5 Meningioma along superior sagittal sinus with invasion of the bone. Five months after discontinuation of CPA 
the initial axial diameter, 39.30mm, was reduced to 36.92mm. Another smaller meningioma is located at the left 
basal frontal base.  
